Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT04373967 ↗

Description as written by the study sponsor.

Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it has physiological effects such as glucose-dependent insulin synthesis and secretion, inhibition of β-cell apoptosis, promotion of β-cell proliferation and regeneration, inhibition of glucagon secretion, reduction of food intake, delay of gastric emptying, enhancement of glucose utilization in peripheral tissues and reduction of glycogen output. Liraglutide injection,developed and marketed as Victoza® by Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved by the U.S. Food and Drug Administration in 2010.This 26-week trial compares the effectivity on glycaemic control,safety and immunogenicity of liraglutide injection and Victoza® in patients with type 2 diabetes inadequately controlled by oral metformin alone.

Treatments tested

• Victoza®. Drug

  Patients will receive Victoza®. Both products will be provided as pen-injector.

• Metformin Hydrochloride Drug

  Patients who were receiving metformin prior to study will continue to receive it during the study.

• TQZ2451 Drug

  Patients will receive TQZ2451.Both products will be provided as pen-injector.